Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid.

Literature DB >> 19933794

Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid.

Asma Lat¹, George R Thompson, Michael G Rinaldi, Sheryl A Dorsey, Gennethel Pennick, James S Lewis.

Abstract

We report the attainment of micafungin concentrations from brain tissue and pancreatic pseudocyst fluid from two patients with invasive candidiasis. Micafungin was present in low levels at both body sites, indicating limited penetration into central nervous system (CNS) tissue and pancreatic fluid. Further studies are needed to fully characterize its pharmacokinetics at these locations, as micafungin may potentially serve as an alternative antifungal therapy for CNS or pancreatic candidal infections for which the currently recommended first-line therapy fails.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19933794 PMCID： PMC2812135 DOI： 10.1128/AAC.01294-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

Authors: Joseph S Solomkin; John E Mazuski; Ellen J Baron; Robert G Sawyer; Avery B Nathens; Joseph T DiPiro; Timothy Buchman; E Patchen Dellinger; John Jernigan; Sherwood Gorbach; Anthony W Chow; John Bartlett
Journal: Clin Infect Dis Date: 2003-09-25 Impact factor: 9.079

Review 2. Clinical practice. Acute pancreatitis.

Authors: David C Whitcomb
Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245

3. Practice guidelines in acute pancreatitis.

Authors: Peter A Banks; Martin L Freeman
Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864

4. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Authors: Nita L Seibel; Cindy Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edith Albano; James Keirns; Wendi M Lau; David P Facklam; Donald N Buell; Thomas J Walsh
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191

5. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Authors: Mary F Hebert; Helen E Smith; Thomas C Marbury; Suzanne K Swan; William B Smith; Robert W Townsend; Donald Buell; James Keirns; Ihor Bekersky
Journal: J Clin Pharmacol Date: 2005-10 Impact factor: 3.126

6. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

Authors: Vidmantas Petraitis; Ruta Petraitiene; Andreas H Groll; Kristin Roussillon; Melissa Hemmings; Caron A Lyman; Tin Sein; John Bacher; Ihor Bekersky; Thomas J Walsh
Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191

7. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.

Authors: A H Groll; D Mickiene; V Petraitis; R Petraitiene; K H Ibrahim; S C Piscitelli; I Bekersky; T J Walsh
Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191

8. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors: Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal: Lancet Date: 2007-05-05 Impact factor: 79.321

9. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy.

Authors: Jan J De Waele; D Vogelaers; S Blot; F Colardyn
Journal: Clin Infect Dis Date: 2003-07-09 Impact factor: 9.079

10. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors: Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079

13 in total

Review 1. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors: Romuald Bellmann; Piotr Smuszkiewicz
Journal: Infection Date: 2017-07-12 Impact factor: 3.553

Review 2. Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors: Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal: Med Mycol Date: 2019-04-01 Impact factor: 4.076

3. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.

Authors: Michaela Lackner; G Sybren de Hoog; Paul E Verweij; Mohammad J Najafzadeh; Ilse Curfs-Breuker; Corné H Klaassen; Jacques F Meis
Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191

Review 4. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.

Authors: Effie L Kuti; Joseph L Kuti
Journal: Expert Opin Drug Metab Toxicol Date: 2010-10 Impact factor: 4.481